School of Medicine
Showing 1-8 of 8 Results
-
Sharada Kalanidhi
Director of Data Science, Biochemistry - Genome Center
Current Role at StanfordCurrent Research: Mathematical Medicine
The essential challenge is not merely to solve a problem, but to discover the mathematical framework in which the problem can be understood — a perspective associated with the mathematician Alexander Grothendieck.
We spent decades using sophisticated mathematics to understand financial markets. What happens when we bring that same mathematical direction—and deeper ideas from pure mathematics—to understanding human biology?
This question captures the intellectual motivation behind Sharada's current work: developing the foundations of Mathematical Medicine, a proposed new discipline that draws on pure mathematics to address fundamental challenges in individualized diagnosis, personalized therapeutics, cancer treatments, and healthy longevity.
The work begins with a central challenge in contemporary medicine. Advances in genomics, proteomics, metabolomics, and computational biology have generated unprecedented volumes of biomedical data. Yet translating these measurements into meaningful insights for individual patients remains difficult, particularly for those with rare, complex, or previously unexplained conditions.
Conventional statistical and machine learning approaches have transformed biomedical research, but their reliance on population-level patterns can limit their usefulness when an individual patient's biology differs substantially from that of available reference cohorts. Clinically meaningful differences may be treated as statistical noise or outliers rather than investigated as potential clues to underlying disease mechanisms.
After more than a decade of research and collaboration with biochemists at SGTC, Sharada became increasingly interested in whether the mathematical foundations used to interpret biomedical data were sufficient for the complexity of individualized medicine.
Her central premise is that progress in personalized medicine may require not simply more data or larger computational models, but new mathematical ways of understanding biological systems.
Rather than applying existing statistical approaches to biomedical problems, Mathematical Medicine explores whether ideas from pure mathematics can fundamentally change how biological questions are formulated, understood, and solved.
The research is guided by the possibility that deeper mathematical understanding can reveal - and preserve- meaningful biological relationships even when data are limited, heterogeneous, or difficult to interpret using conventional approaches.
This approach echoes a perspective expressed by the mathematician Mikhail Gromov: “This area does not yet exist. It will have to be invented.”
It also reflects the empirical philosophy associated with the mathematician and quantitative investor Jim Simons: “We don't start with models. We start with data. We don't have any preconceived notions.” The aim is to allow biological observations to guide mathematical inquiry, rather than forcing them into existing computational frameworks.
Sharada's research has contributed to investigations of complex and previously unexplained clinical conditions, including cases in which mathematical and multi-omic analyses helped identify potential diagnoses and therapeutic pathways. These investigations also motivate broader questions about how individual biological differences can inform our understanding of disease.
The long-term vision is to establish Mathematical Medicine as a rigorous discipline connecting pure mathematics, molecular biology, and clinical medicine—advancing mathematics toward a foundation for understanding individual biology, preserving biological mechanisms and informing clinical decisions.
Further information about Mathematical Medicine, its research vision, and opportunities for early philanthropic partnerships is available at:
https://mathmed-2026.web.app/ -
Preston Kellenberger
Ph.D. Student in Biochemistry, admitted Autumn 2025
BioI was raised in Saint Louis County, MO and completed my undergraduate degree in Biochemistry at The University of Missouri – Columbia. I’m most excited by translational problems that can be addressed through the structural understanding and engineering of biological molecules. At Stanford, I look forward to joining a collaborative community that spans broad scientific disciplines, and to contributing to research that advances human health. I love spending my extra time playing the drums, and I have served as a snare drummer for the world-class Madison Scouts and Cavaliers drum corps.
-
Chaitan Khosla
Wells H. Rauser and Harold M. Petiprin Professor and Professor of Chemistry and, by courtesy, of Biochemistry
Current Research and Scholarly InterestsResearch in this laboratory focuses on problems where deep insights into enzymology and metabolism can be harnessed to improve human health.
For the past two decades, we have studied and engineered enzymatic assembly lines called polyketide synthases that catalyze the biosynthesis of structurally complex and medicinally fascinating antibiotics in bacteria. An example of such an assembly line is found in the erythromycin biosynthetic pathway. Our current focus is on understanding the structure and mechanism of this polyketide synthase. At the same time, we are developing methods to decode the vast and growing number of orphan polyketide assembly lines in the sequence databases.
For more than a decade, we have also investigated the pathogenesis of celiac disease, an autoimmune disorder of the small intestine, with the goal of discovering therapies and related management tools for this widespread but overlooked disease. Ongoing efforts focus on understanding the pivotal role of transglutaminase 2 in triggering the inflammatory response to dietary gluten in the celiac intestine. -
Peter S. Kim
Virginia and D. K. Ludwig Professor of Biochemistry
Current Research and Scholarly InterestsOur research focuses on developing new strategies for vaccine creation. We also aim to generate vaccines targeting infectious agents that have eluded efforts to date. We integrate experimental approaches with protein language models to guide artificial evolution and enable efficient antibody and protein engineering. Our interdisciplinary approach aims to address critical global health challenges.
-
Silvana Maria Konermann
Assistant Professor of Biochemistry
BioSilvana is an Assistant Professor of Biochemistry at Stanford and Executive Director and Core Investigator at Arc Institute. Her research laboratory aims to understand the molecular pathways that drive the development of Alzheimer’s disease using next-generation functional genomics, with the long-term goal of developing rationally targeted therapeutics for neurodegenerative disorders. She received her Ph.D. in Neuroscience from MIT. Silvana’s pioneering work on tools to directly perturb the transcriptomic landscape of the cell using CRISPR has been recognized by her faculty appointment as a Chan Zuckerberg Biohub Investigator and Hanna Gray Fellow of the Howard Hughes Medical Institute.
-
Mark Krasnow
Paul and Mildred Berg Professor
Current Research and Scholarly Interests- Lung development and stem cells
- Neural circuits of breathing and speaking
- Lung diseases including lung cancer
- New genetic model organism for biology, behavior, health and conservation